Pharmacological Action of Tigecycline

  • Author:Ray Dean
  • Release on :2016-07-26

Tigecycline is the first new approved intravenous use glycyl tetracyclines, broad-spectrum antimicrobial activity, for the treatment of Gram-negative or positive pathogens, anaerobes and methicillin-resistant Staphylococcus GPB (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA) caused clA1, DSSSI, tigecycline to doctors who provided a new, early treatment can cause not understand when the time for a wide selection of antibiotics and had no need to adjust the dose with impaired renal function, easy to use, can be taken once every 12 hours. The most common adverse reactions were nausea (29.5%) and vomiting (9.7%). The antibacterial mechanism to inhibit bacterial protein synthesis by blocking the amino acyl tRNA into the A site of the ribosome.


Clinical studies have shown tigecycline may be used Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus angina, pyogenic streptococci and Bacteroides fragilis, Fei Citrobacter , Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis, Staphylococcus aureus, Streptococcus angina, Bacteroides fragilis, Bacteroides pleomorphic, simplex Bacteroides, Bacteroides ordinary, adult abdominal Clostridium perfringens, small Peptostreptococcus infection caused (cIAI) and complicated skin and soft tissue infections (cSSSI).


Hubei Ocean Biotech Co., Ltd, a leading professional chemical industry enterprise with integrating production and trade for global valued customer with our superior quality and reliable cooperation. Should you have any interest in our APIs Pharma Products, welcome to take view at our site and be feel free to contact me.